Unicycive Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.71
- Today's High:
- $0.737
- Open Price:
- $0.727
- 52W Low:
- $0.4
- 52W High:
- $2.87
- Prev. Close:
- $0.716
- Volume:
- 14556
Company Statistics
- Market Cap.:
- $27.80 million
- Book Value:
- -1.271
- Revenue TTM:
- $1.63 million
- Operating Margin TTM:
- -1193.3%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -67.94%
- Return on Equity TTM:
- -350.04%
Company Profile
Unicycive Therapeutics Inc had its IPO on 2021-07-12 under the ticker symbol UNCY.
The company operates in the Healthcare sector and Biotechnology industry. Unicycive Therapeutics Inc has a staff strength of 12 employees.
Stock update
Shares of Unicycive Therapeutics Inc opened at $0.73 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.71 - $0.74, and closed at $0.74.
This is a +2.93% increase from the previous day's closing price.
A total volume of 14,556 shares were traded at the close of the day’s session.
In the last one week, shares of Unicycive Therapeutics Inc have slipped by -7.88%.
Unicycive Therapeutics Inc's Key Ratios
Unicycive Therapeutics Inc has a market cap of $27.80 million, indicating a price to book ratio of 2.4394 and a price to sales ratio of 11.184.
In the last 12-months Unicycive Therapeutics Inc’s revenue was $1.63 million with a gross profit of $0 and an EBITDA of $-19396000. The EBITDA ratio measures Unicycive Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Unicycive Therapeutics Inc’s operating margin was -1193.3% while its return on assets stood at -67.94% with a return of equity of -350.04%.
In Q2, Unicycive Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Unicycive Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Unicycive Therapeutics Inc’s profitability.
Unicycive Therapeutics Inc stock is trading at a EV to sales ratio of 4.6991 and a EV to EBITDA ratio of -0.2912. Its price to sales ratio in the trailing 12-months stood at 11.184.
Unicycive Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $22.88 million
- Total Liabilities
- $15.42 million
- Operating Cash Flow
- $-12000.00
- Capital Expenditure
- $12000
- Dividend Payout Ratio
- 0%
Unicycive Therapeutics Inc ended 2024 with $22.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.88 million while shareholder equity stood at $6.83 million.
Unicycive Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $15.42 million in other current liabilities, 15000.00 in common stock, $-52410000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.82 million and cash and short-term investments were $18.82 million. The company’s total short-term debt was $303,000 while long-term debt stood at $0.
Unicycive Therapeutics Inc’s total current assets stands at $21.93 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $446000.00 and inventory worth $0.
In 2024, Unicycive Therapeutics Inc's operating cash flow was $-12000.00 while its capital expenditure stood at $12000.
Comparatively, Unicycive Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.74
- 52-Week High
- $2.87
- 52-Week Low
- $0.4
- Analyst Target Price
- $4.6
Unicycive Therapeutics Inc stock is currently trading at $0.74 per share. It touched a 52-week high of $2.87 and a 52-week low of $2.87. Analysts tracking the stock have a 12-month average target price of $4.6.
Its 50-day moving average was $1 and 200-day moving average was $1.13 The short ratio stood at 0.98 indicating a short percent outstanding of 0%.
Around 4149.3% of the company’s stock are held by insiders while 4674.4% are held by institutions.
Frequently Asked Questions About Unicycive Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.